Samsung Biologics Co Ltd Total Liabilities
Samsung Biologics Co Ltd total liabilities. Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has total liabilities worth ₩4.29 Trillion KRW (≈ $2.91 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 207940 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Samsung Biologics Co Ltd (2014–2025)
Total liabilities of Samsung Biologics Co Ltd from 2014 to 2025. This chart illustrates how Samsung Biologics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Samsung Biologics Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Samsung Biologics Co Ltd Competitors by Total Liabilities
The table below lists competitors of Samsung Biologics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vistra Energy Corp
NYSE:VST
|
USA | $32.80 Billion |
|
Polski Koncern Naftowy ORLEN SA
WAR:PKN
|
Poland | zł120.50 Billion |
|
Waste Connections Inc
TO:WCN
|
Canada | CA$13.46 Billion |
|
SIEMENS HEALTH ADR/050
F:SHL1
|
Germany | €25.79 Billion |
|
State Street Corp
NYSE:STT
|
USA | $390.11 Billion |
|
Nike Inc
NYSE:NKE
|
USA | $22.97 Billion |
|
Hangzhou Hikvision Digital Technology Co Ltd
SHE:002415
|
China | CN¥44.56 Billion |
|
COMPASS GROUP
F:XGR
|
Germany | €18.95 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Samsung Biologics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Samsung Biologics Co Ltd.
Liquidity & Leverage Metrics
Samsung Biologics Co Ltd Total Liabilities Ratios Explained
Samsung Biologics Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Samsung Biologics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Samsung Biologics Co Ltd (2014–2025)
The table below shows the annual total liabilities of Samsung Biologics Co Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩3.61 Trillion ≈ $2.45 Billion |
-43.88% |
| 2024-12-31 | ₩6.43 Trillion ≈ $4.36 Billion |
+3.47% |
| 2023-12-31 | ₩6.22 Trillion ≈ $4.21 Billion |
-18.19% |
| 2022-12-31 | ₩7.60 Trillion ≈ $5.15 Billion |
+155.05% |
| 2021-12-31 | ₩2.98 Trillion ≈ $2.02 Billion |
+63.19% |
| 2020-12-31 | ₩1.83 Trillion ≈ $1.24 Billion |
+17.23% |
| 2019-12-31 | ₩1.56 Trillion ≈ $1.06 Billion |
-14.67% |
| 2018-12-31 | ₩1.82 Trillion ≈ $1.24 Billion |
-43.09% |
| 2017-12-31 | ₩3.21 Trillion ≈ $2.17 Billion |
-7.07% |
| 2016-12-31 | ₩3.45 Trillion ≈ $2.34 Billion |
+8.32% |
| 2015-12-31 | ₩3.19 Trillion ≈ $2.16 Billion |
+339.42% |
| 2014-12-31 | ₩724.97 Billion ≈ $491.30 Million |
-- |
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offe… Read more